2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Apical Sodium-Dependent Bile Acid Transporter
  5. Apical Sodium-Dependent Bile Acid Transporter Inhibitor

Apical Sodium-Dependent Bile Acid Transporter Inhibitor

Apical Sodium-Dependent Bile Acid Transporter Inhibitors (4):

Cat. No. Product Name Effect Purity
  • HY-109120
    Odevixibat
    		Inhibitor 99.92%
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis.
  • HY-15790
    Elobixibat
    		Inhibitor 99.88%
    Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC50 value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
  • HY-16747
    Maralixibat chloride
    		Inhibitor 99.08%
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.
  • HY-148795
    Ritivixibat
    		Inhibitor
    Ritivixibat is an inhibitor of ileal bile acid transporter (IBAT), as well as a bile acid modulator. Ritivixibat can be used for research of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.